Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

One significant element is Pfizer’s recent focus on cancer cachexia and the promising results of their drug ponsegromab in Phase 2 trials. Although ponsegromab showed a clinically meaningful ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower cholesterol, resulting in buyers paying ...

Pfizer's COVID-19 products continue to generate significant cash flow that helps bolster the company's dividend. The big drugmaker has opportunities to monetize assets to raise additional cash ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year A boost from COVID-19 treatment sales helped bush Pfizer to a ...

On behalf of the Pfizer team, thank you for joining us ... by the potential for a breakthrough for patients with cancer cachexia, who lack treatment options for this life whitening wasting ...

Pfizer offers a generous 5.73% dividend yield. The stock is trading at an attractive forward P/E of 9.5x 2026 earnings. The company has multiple potential growth drivers in its pipeline. Pfizer's ...

Pfizer is making strides in the rapidly growing weight management market. The company is committed to developing a franchise around obesity and cachexia treatments. This focus aligns with the ...

NEW YORK, Oct 15 (Reuters) - Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as it faces pressure from activist hedge fund ...

Third-Quarter 2024 Reported (4) Diluted EPS of $0.78 and Adjusted (2) Diluted EPS of $1.06 On Track to Deliver Net Cost Savings of At Least $5.5 Billion from Previously Announced Cost Reduction ...